Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Is All-Cause Mortality an Optimal Endpoint for HABP/VABP Trials? A Reflection on a Recent Meta-Analysis.

Created on 12 Aug 2026

Authors

Shan Qingqing

Published in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Aug 12, 2026. Epub Aug 12, 2026.

PMID:
42584229
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement